Oncology biotech Immix Biopharma files for a $25 million IPO
September 17, 2021
Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, filed on Friday with the SEC to raise up to $25 million in an initial public offering.
Immix is developing a novel class of Tissue-Specific Therapeutics (“TSTx”) in oncology and inflammation. Its lead asset, IMX-110, is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer. IMX-110 is currently in Phase 1b/2a trials for solid tumors in the US and Australia.
The Los Angeles, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol IMMX. Immix Biopharma filed confidentially on July 20, 2021.
Comments are closed